

GenScript ProBio signs MoU with ACT Therapeutics to develop new CAR-T cell therapies

13 July 2022 | News

To accelerate the development of treatments targeting refractory and intractable solid cancers

GenScript ProBio, a global CDMO, and South Korea-based ACT Therapeutics have entered into a strategic partnership MoU concerning the development of a new CAR-T cell therapies. GenScript ProBio and ACT Therapeutics have agreed to strengthen their cooperation in the cell therapy field through this MoU.

GenScript ProBio and ACT Therapeutics are in the process of signing a contract for plasmid and virus vector development and production for the first pipeline of ACT Therapeutics' Advanced CAR-T Platform (ACT platform), which will also be commissioned to produce raw materials for ACT Therapeutics' subsequent pipeline.

With this agreement, GenScript ProBio has become a global partner that can support ACT platforms for ACT therapeutics.

The ACT platform is an immune cell-based next-generation cell and gene therapy technology that uses virus vectors to insert genes designed to target cancer antigens into immune cells. GenScript ProBio has a high-quality virus vector process development and one-stop service platform for GMP production required for cell and gene therapy development.

Image credit- Left–Seogkyoung-Kong CEO of ACT THERAPEUTICS/Right-Brian H. Min CEO of GenScript ProBio